These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 11429210)

  • 1. Patterns and fate of PSA bouncing following 3D-CRT.
    Hanlon AL; Pinover WH; Horwitz EM; Hanks GE
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):845-9. PubMed ID: 11429210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-Specific Antigen (PSA) Bounces Following Stereotactic Body Radiotherapy for Prostate Cancer: Importance of PSA Test Frequency.
    Kang KM; Choi HS; Jang HS; Song JH
    Urol J; 2024 Jun; ():. PubMed ID: 38863321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resilience and health-Can we aspire to more than just bouncing back?
    Rosen SD
    Future Healthc J; 2024 Mar; 11(1):100026. PubMed ID: 38646059
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-Specific Antigen Bounce after
    Kim TH; Lee JJB; Cho J
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine.
    Meehan J; Gray M; Martínez-Pérez C; Kay C; McLaren D; Turnbull AK
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.
    Nakamura K; Ikeda I; Inokuchi H; Takayama K; Inoue T; Kamba T; Ogawa O; Hiraoka M; Mizowaki T
    J Radiat Res; 2018 Sep; 59(5):656-663. PubMed ID: 30085048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up.
    Makarewicz R; Lebioda A; Terlikiewicz J; Biedka M; Wiśniewski T
    J Contemp Brachytherapy; 2009 Jun; 1(2):92-96. PubMed ID: 27795718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Follow-up of urological tumor treatment].
    Ohlmann CH; Albers P; Boehm K; Graefen M; Hakenberg OW; Kuczyk M; Graf J; Peters I; Protzel C
    Urologe A; 2015 Sep; 54(9):1223-33. PubMed ID: 26246111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.
    Vu CC; Haas JA; Katz AE; Witten MR
    Front Oncol; 2014; 4():8. PubMed ID: 24478988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis.
    Bernstein MB; Ohri N; Hodge JW; Garg M; Bodner W; Kalnicki S; Dicker AP; Guha C
    J Contemp Brachytherapy; 2013 Dec; 5(4):210-4. PubMed ID: 24474969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of biochemical recurrence after primary localized therapy for prostate cancer.
    Darwish OM; Raj GV
    Front Oncol; 2012; 2():48. PubMed ID: 22655274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.
    Mazeron R; Bajard A; Montbarbon X; Gassa F; Malet C; Rocher F; Clippe S; Bringeon G; Desmettre O; Pommier P
    Radiat Oncol; 2012 Mar; 7():46. PubMed ID: 22449081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.
    Franiel T; Hamm B; Hricak H
    Eur Radiol; 2011 Mar; 21(3):616-26. PubMed ID: 21184082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer.
    Kanai K; Nakashima J; Sugawara A; Shigematsu N; Nagata H; Kikuchi E; Miyajima A; Nakagawa K; Kubo A; Oya M
    Int J Clin Oncol; 2009 Dec; 14(6):502-6. PubMed ID: 19967485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.
    Zapotoczna A; Sasso G; Simpson J; Roach M
    Neoplasia; 2007 Jun; 9(6):455-63. PubMed ID: 17603627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effective management of biochemical recurrence in patients with prostate cancer.
    McLeod DG
    Rev Urol; 2005; 7 Suppl 5(Suppl 5):S29-36. PubMed ID: 16985881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost.
    Singh AK; Guion P; Susil RC; Citrin DE; Ning H; Miller RW; Ullman K; Smith S; Crouse NS; Godette DJ; Stall BR; Coleman CN; Camphausen K; Ménard C
    Radiat Oncol; 2006 Aug; 1():28. PubMed ID: 16914054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best practice in primary care pathology: review 4.
    Smellie WS; Forth J; Sundar S; Kalu E; McNulty CA; Sherriff E; Watson ID; Croucher C; Reynolds TM; Carey PJ
    J Clin Pathol; 2006 Sep; 59(9):893-902. PubMed ID: 16714397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy.
    Stephenson AJ; Scardino PT; Bianco FJ; Eastham JA
    Curr Treat Options Oncol; 2004 Oct; 5(5):357-65. PubMed ID: 15341674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.